Compare CVS Health Corp (CVS) vs Trade Desk Inc (TTD) Price & Performance

CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.

The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.

The Trade Desk (TTD) is trading at $13.80, down 21.9% in 24 hours and near 7-year lows following disappointing Q2 earnings. Revenue grew just 3% to $715 million, missing guidance, while Q3 guidance projects a 12% decline. Technical indicators show bearish momentum with support at $13 and resistance at $15. Despite strong profitability metrics including 76.9% gross margins, recent execution gaps and advertiser pressure have triggered multiple analyst downgrades.

The outlook remains challenging with near-term revenue headwinds and competitive pressures. While valuation appears reasonable at 16.4x P/E, the stock faces significant execution risks and sentiment deterioration. Recovery depends on stabilizing advertiser relationships and reversing recent market share losses in the ad-tech sector.